Immunomodulation Therapy; L2 (11-11-15) Flashcards
Glucocorticoids (Prednisone, Prednisolone) - Indications
- __
- To prevent __ rejection
- To prevent __
- Tx of __-release syndrome
- Tx of a wide variety of ___ and __ diseases, e.g., RA, SLE, asthma, etc.
Glucocorticoids (Prednisone, Prednisolone) - Indications
- Immunosuppression
- To prevent graft rejection
- To prevent GvHD
- Tx of cytokine-release syndrome
- Tx of a wide variety of autoimmune and inflammatory diseases, e.g., RA, SLE, asthma, etc.
Glucocorticoids (Prednisone, Prednisolone) - MOA
- Activates the __ receptor transcription factor
- Modifies expression of __ and other __regulatory genes
- Suppresses active __ responses
Glucocorticoids (Prednisone, Prednisolone) - MOA
- Activates the glucocorticoid receptor transcription factor
- Modifies expression of cytokine and other immunoregulatory genes
- Suppresses active immune responses
Glucocorticoids (Prednisone, Prednisolone) - Adverse Effects
- MANY adverse effects
- __glycemia
- __tension
- __lipidemia
- Obesity
- Diabetes
- Poor __ healing
- Mania and psychosis
- Increased risk of __
Glucocorticoids (Prednisone, Prednisolone) - Adverse Effects
- MANY adverse effects
- Hyperglycemia
- Hypertension
- Hyperlipidemia
- Obesity
- Diabetes
- Poor wound healing
- Mania and psychosis
- Increased risk of infections
Glucocorticoids (Prednisone, Prednisolone) - Misc
- Glucocorticoid dose should be __ reduced to minimize adverse effects
- Glucocorticoids should NOT be __ __
Glucocorticoids (Prednisone, Prednisolone) - Misc
- Glucocorticoid dose should be gradually reduced to minimize adverse effects
- Glucocorticoids should NOT be withdrawn abruptly
Azathioprine - Indications
- __
- To prevent __ rejection
- To prevent __
- Tx of __ diseases
Azathioprine - Indications
- Immunosuppression
- To prevent graft rejection
- To prevent GvHD
- Tx of autoimmune diseases
Azathioprine - MOA
- __
- Converted to _-__ by __
- Inhibits de novo __ synthesis
- Incorporated into DNA and causes __ base mispairing -> apoptosis
- Inhibits __ co-stimulation
Azathioprine - MOA
- Prodrug
- Converted to 6-MP by HGPRT
- Inhibits de novo purine synthesis
- Incorporated into DNA and causes SS base mispairing -> apoptosis
- Inhibits CD28 co-stimulation
Azathioprine - Adverse Effects
- __penia/__penia
- __toxicity
- Increased risk of __
- Increased risk of __
Azathioprine - Adverse Effects
- Leukopenia/thrombocytopenia
- Hepatotoxicity
- Increased risk of infections
- Increased risk of malignancy
Azathioprine - Misc
-Interacts with __-__ drugs (__ and __) -> __ [azathioprine] -> increased __
Azathioprine - Misc
-Interacts with anti-gout drugs (allopurinol and febuxostat) -> increased [azathioprine] -> increased toxicity
Mycophenolate Mofetil - Indications
- __
- To prevent __ rejection
- To prevent __
- Tx of __ diseases
Mycophenolate Mofetil - Indications
- Immunosuppression
- To prevent graft rejection
- To prevent GvHD
- Tx of autoimmune diseases
Mycophenolate Mofetil - MOA
- __
- Converted to __ __
- Inhibits __ __ (IMPDH) type II (selectively expressed in __) -> inhibition of __ nucleotide synthesis - no __ pathway in lymphocytes
Mycophenolate Mofetil - MOA
- Prodrug
- Converted to mycophenolic acid
- Inhibits inosine monophosphatedehydrogenase (IMPDH) type II (selectively expressed in lymphocytes) -> inhibition of purine nucleotide synthesis - no salvage pathway in lymphocytes
Mycophenolate Mofetil - Adverse Effects
- __penia/anemia
- __ (male/female)
- Increased risk of __
- Increased risk of __
-RARE - __ __ __ __ __ (PML) - fatal viral disease caused by reactivation of JC virus
Mycophenolate Mofetil - Adverse Effects
- Leukopenia/anemia
- Teratogenic (male/female)
- Increased risk of infections
- Increased risk of malignancy
-RARE - Risk of Progressive Multifocal Leukoencephalopathy (PML) - fatal viral disease caused by reactivation of JC virus
Mycophenolate Mofetil - Misc
-Contraindicated in __, women who wish to __ __, and men who wish to __ __
Mycophenolate Mofetil - Misc
-Contraindicated in pregnancy, women who wish to become pregnant, and men who wish to become fathers
Calcineurin Inhibitors (Cyclosporine, Tacrolimus) - Indications
- __
- To prevent __ rejection
- To prevent __
- Tx of __ diseases
Calcineurin Inhibitors (Cyclosporine, Tacrolimus) - Indications
- Immunosuppression
- To prevent graft rejection
- To prevent GvHD
- Tx of autoimmune diseases
Calcineurin Inhibitors (Cyclosporin, Tacrolimus) - MOA
- Cyclosporin and tacrolimus bind __ and __, respectively, to form inhibitory complexes
- __/cyclosporin and __/tacrolimus complexes inhibit the Ca2+-regulated phosphatase, __
- Inhibition of __ inhibits the activation of the __ transcription factor, which is involved in regulating the expression of IL-__ and multiple other immunoregulatory genes
- Potently inhibit the T-cell immune response by inhibiting signal __
Calcineurin Inhibitors (Cyclosporin, Tacrolimus) - MOA
- Cyclosporin and tacrolimus bind cyclophilin and FKBP, respectively, to form inhibitory complexes
- Cyclophilin/cyclosporin and FKBP/tacrolimus complexes inhibit the Ca2+-regulated phosphatase, calcineurin
- Inhibition of calcineurin inhibits the activation of the NFAT transcription factor, which is involved in regulating the expression of IL-2 and multiple other immunoregulatory genes
- Potently inhibit the T-cell immune response by inhibiting signal 1
Calcineurin Inhibitors (Cyclosporine, Tacrolimus) - Adverse Effects
- **__**
- __tension
- __toxicity/tremor
- Glucose intolerance ( __ > __ )
- Hyperlipidemia ( __ > __ )
- Hypertrichosis (__)
- Alopecia (__)
- Increased risk of __
- Increased risk of __
Calcineurin Inhibitors (Cyclosporine, Tacrolimus) - Adverse Effects
- **Nephrotoxicity**
- Hypertension
- Neurotoxicity/tremor
- Glucose intolerance ( T > C )
- Hyperlipidemia ( C > T )
- Hypertrichosis (C)
- Alopecia (T)
- Increased risk of infections
- Increased risk of malignancy
Calcineurin Inhibitors (Cyclosporine, Tacrolimus) - Misc
- Metabolized by CYP3A4 -> MANY drug interactions
- 3A4 inhibitors promote __ drug levels -> increased risk of __
- 3A4 inducers promote __ drug levels -> increased risk of __ rejection
Calcineurin Inhibitors (Cyclosporine, Tacrolimus) - Misc
- Metabolized by CYP3A4 -> MANY drug interactions
- 3A4 inhibitors promote increased drug levels -> increased risk of toxicity
- 3A4 inducers promote decreased drug levels -> increased risk of graft rejection
mTor Inhibitors (Sirolimus, Everolimus) - Indications
- __
- To prevent __ rejection (but NOT __, NOT __)
- To prevent __
- Included in __ stents to inhibit re__
mTor Inhibitors (Sirolimus, Everolimus) - Indications
- Immunosuppression
- To prevent graft rejection (NOT lung, NOT liver)
- To prevent GvHD
- Included in arterial stents to inhibit restenosis
mTor Inhibitors (Sirolimus, Everolimus) - MOA
- Drugs form complex with __
- __/drug complex inhibits IL-__ mediated activation of mTor kinase (T-cell signal __)
- Inhibits IL-__ stimulated protein synthesis, cell proliferation, and survival
mTor Inhibitors (Sirolimus, Everolimus) - MOA
- Drugs form complex with FKBP
- FKBP/drug complex inhibits IL-2 mediated activation of mTor kinase (T-cell signal 2)
- Inhibits IL-2 stimulated protein synthesis, cell proliferation, and survival
mTor Inhibitors (Sirolimus, Everolimus) - Adverse Effects
- __triglyceridemia
- __cholesterolemia
- Increased __ disease
- Increased risk of __
- Anemia, thrombocytopenia, and leukopenia
- Decreased __ healing
- Teratogenic
- Increased risk of __
- Increased risk of __
mTor Inhibitors (Sirolimus, Everolimus) - Adverse Effects
- Hypertriglyceridemia
- Hypercholesterolemia
- Increased lung disease
- Increased risk of diabetes
- Anemia, thrombocytopenia, and leukopenia
- Decreased wound healing
- Teratogenic
- Increased risk of infections
- Increased risk of malignancy
mTor Inhibitors (Sirolimus, Everolimus) - Misc
- Metabolized by __
- Many drug interactions
- Contraindicated in __
- NOT RECOMMENDED in __ transplantation (risk anastomotic dehiscence), __ transplantation (risk __ artery thrombosis)
mTor Inhibitors (Sirolimus, Everolimus) - Misc
- Metabolized by CYP3A4
- Many drug interactions
- Contraindicated in pregnancy
- NOT RECOMMENDED in lung transplantation (risk anastomotic dehiscence), liver transplantation (risk hepatic artery thrombosis)
Rabbit anti-thymocyte globulin - Indications
-Induction __therapy
Rabbit anti-thymocyte globulin - Indications
-Induction immunotherapy
Rabbit anti-thymocyte globulin - MOA
- Rabbit __clonal antibodies specific for human __
- Depletes __ from the blood
Rabbit anti-thymocyte globulin - MOA
- Rabbit polyclonal antibodies specific for human lymphocytes
- Depletes lymphocytes from the blood
Rabbit anti-thymocyte globulin - Adverse Effects
- __ release syndrome
- __penia
Rabbit anti-thymocyte globulin - Adverse Effects
- Cytokine release syndrome
- Leukopenia
Alemtuzumab - Indications
-Induction __therapy
Alemtuzumab - Indications
-Induction immunotherapy